Jose Cortina
About Jose Cortina
Jose Cortina serves as the South Central Zone Business Director for Rare Disease at Travere Therapeutics, where he focuses on product advocacy and disease awareness. He has extensive experience in the pharmaceutical industry, having held various roles in companies such as UCB Pharma, Reata Pharmaceuticals, and Pfizer.
Current Role at Travere Therapeutics
Jose Cortina serves as the South Central Zone Business Director for Rare Disease at Travere Therapeutics. He has held this position since 2022 and is based in Austin, Texas. In this role, he specializes in IV infusion and injectables, focusing on product advocacy and increasing disease awareness within the rare disease market.
Previous Experience in Rare Disease and Immunology
Before joining Travere Therapeutics, Jose Cortina worked at Reata Pharmaceuticals, Inc. as the Regional Business Director for South Central, Rare Disease Nephrology for a brief period in 2021-2022. He also spent five years at UCB Pharma as a Senior Immunology Specialist in the Immunology/Inflammatory Disease Division from 2006 to 2011, where he developed expertise in the field.
Educational Background
Jose Cortina studied at the University of California, Irvine, where he earned a Bachelor of Science in Biochemistry and Molecular Biology. He also holds a Bachelor of Arts in History from the same institution, showcasing a diverse academic background.
Sales and Market Expertise
Jose Cortina possesses extensive experience in sales force training and development. He has a strong background in buy and bill processes and specialty pharmacy operations. His skills include territory development and market penetration strategies, which contribute to his effectiveness in the pharmaceutical industry.
Career Timeline and Roles
Jose Cortina's career includes various roles in the pharmaceutical industry. He worked at InterMune as a Pulmonary Specialist from 2002 to 2006, at Pfizer as a Territory Manager in the Women’s Healthcare Division from 1999 to 2002, and at Vertex Pharmaceuticals as an HCV Therapeutic Specialist from 2011 to 2013. His diverse roles reflect his adaptability and breadth of knowledge in different therapeutic areas.